Article thumbnail

The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects

By Beáta Sperlágh and E. Sylvester Vizi


Now there is general agreement that the purine nucleoside adenosine is an important neuromodulator in the central nervous system, playing a crucial role in neuronal excitability and synaptic/non-synaptic transmission in the hippocampus and basal ganglia. Adenosine is derived from the breakdown of extra- or intracellular ATP and is released upon a variety of physiological and pathological stimuli from neuronal and non-neuronal sources, i.e. from glial cells and exerts effects diffusing far away from release sites. The resultant elevation of adenosine levels in the extracellular space reaches micromolar level, and leads to the activation A1, A2A, A2B and A3 receptors, localized to pre- and postsynaptic as well as extrasynaptic sites. Activation of presynaptic A1 receptors inhibits the release of the majority of transmitters including glutamate, acetylcholine, noradrenaline, 5-HT and dopamine, whilst the stimulation of A2A receptors facilitates the release of glutamate and acetylcholine and inhibits the release of GABA. These actions underlie modulation of neuronal excitability, synaptic plasticity and coordination of neural networks and provide intriguing target sites for pharmacological intervention in ischemia and Parkinson’s disease. However, despite that adenosine is also released during ischemia, A1 adenosine receptors do not participate in the modulation of excitotoxic glutamate release, which is nonsynaptic and is due to the reverse operation of transporters. Instead, extrasynaptic A1 receptors might be responsible for the neuroprotection afforded by A1 receptor activation

Topics: Article
Publisher: Bentham Science Publishers Ltd
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1978). A Basis for Distinguishing Two Types of Purinergic Receptor. in: cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach.
  2. (1984). A1 and A2 adenosine receptors modulate acetylcholine release from brain slices.
  3. (1995). A1, but not A2A, Adenosine receptors modulate electrically stimulated [14C]acetylcholine release from rat cortex.
  4. (2009). A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease.
  5. (2003). A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
  6. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology,
  7. (1997). Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature,
  8. (2008). Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons.
  9. (1972). Adenine derivatives as neurohumoral agents in the brain. The quantities liberated on excitation of superfused cerebral tissues.
  10. (1997). Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus.
  11. (2006). Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.
  12. (1996). Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.
  13. (2010). Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death. Neuropsychopharmacology,
  14. (1998). Adenosine A1 receptors mediate retinotectal presynaptic inhibition: uncoupling by C-kinase and role in LTP during regeneration.
  15. (2008). Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain.
  16. (2008). Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.
  17. (1997). Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch. Pharmacol.,
  18. (1996). Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in
  19. (2009). Adenosine A2A receptors and Parkinson's disease.
  20. (2009). Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum.
  21. (2002). Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons.
  22. (1990). Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release.
  23. (2005). Adenosine and brain function.
  24. (2001). Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors.
  25. (2001). Adenosine extracellular brain concentrations and role of A2A receptors in
  26. (2001). Adenosine in the central nervous system: release mechanisms and extracellular concentrations.
  27. (1979). Adenosine modulation of synaptosomal dopamine release. Life Sci.,
  28. (2008). Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors.
  29. (2005). Adenosine receptor signaling in the brain immune system. Trends Pharmacol. Sci.,
  30. (1993). Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes.
  31. (2009). Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.
  32. (2009). Adenosine receptors and the central nervous system. Handb Exp Pharmacol.,
  33. (2003). Adenosine receptors in the nervous system: pathophysiological implications.
  34. (1996). Adenosine transporters.
  35. (1997). Adenosine-dopamine receptor-receptor Interactions as an Integrative mechanism in the basal ganglia. Trends Neurosci.,
  36. (2009). Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord.,
  37. (1992). Adenosine: a potential mediator of seizure arrest and postictal refractoriness.
  38. (2007). Advances in the treatment of Parkinson's disease.
  39. (1997). Age-dependent changes of presynaptic neuromodulation via A1-adenosine receptors in rat hippocampal slices.
  40. (1998). An agonist of adenosine A3 receptors decreases Interleukin-12 and Interferon-gamma production and prevents lethality in endotoxemic mice.
  41. (1998). Analysis of purine and pyrimidine bases, nucleosides and deoxynucleosides in brain microsamples (microdialysates and micropunches) and cerebrospinal fluid.
  42. (2001). anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor.
  43. (2000). Association of coffee and caffeine Intake with the risk of Parkinson disease.
  44. (2005). Astrocytic purinergic signaling coordinates synaptic networks.
  45. (2001). ATP mediates calcium signaling between astrocytes and microglial cells: modulation by IFN-gamma.
  46. (2003). ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. Neuron,
  47. (1998). ATP released by LPS increases nitric oxide production in raw 264.7 macrophage cell line via P2Z/P2X7 receptors.
  48. (1996). Autocrine signaling through ATP release represents a novel mechanism for cell volume regulation.
  49. (2009). Axodendritic fibres. of mouse cerebellar granule neurons exhibit a diversity of functional P2X receptors.
  50. (2004). Basal ganglia. In: The Rat Nervous System,
  51. (2009). Blockade of adenosine A2A receptors downregulates DARPP-32 but increases ERK1/2 activity in striatum of dopamine deficient "weaver" mouse.
  52. (2009). Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early
  53. (2009). Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
  54. (2002). Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
  55. (2001). Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.
  56. (1993). Changes in extracellular adenosine during chemical or electrical brain stimulation. Brain Res.,
  57. (1993). Changes in extracellular adenosine levels and population spike amplitude during graded hypoxia in the rat hippocampal slice. Naunyn Schmiedebergs Arch. Pharmacol.,
  58. (1986). Changes in levels of purine and pyrimidine nucleotides during acute hypoxia and recovery in neonatal rat
  59. (1997). Characterization of brain ecto-apyrase: evidence for only one ecto-apyrase (CD39) gene. Brain Res.
  60. (2007). Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus.
  61. (2007). Control of basal extracellular adenosine concentration in rat cerebellum.
  62. (2010). Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors.
  63. (2001). Cytokines and the central nervous system. Brain Res.
  64. (2005). Deletion of presynaptic adenosine A1 receptors impairs the recovery of synaptic transmission after hypoxia. Neuroscience,
  65. (2004). Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in
  66. (1997). Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum.
  67. (2008). Dichotomous dopaminergic control of striatal synaptic plasticity. Science,
  68. (2008). Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocyticdriven volume transmission and synapse-restricted A2A receptormediated facilitation of plasticity.
  69. (2005). Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience,
  70. (1998). Different temperature dependence of carrier-mediated (cytoplasmic) and stimulus-evoked (exocytotic) release of transmitter: a simple method to separate the two types of release.
  71. (2000). Direct measurement of adenosine release during hypoxia in the CA1 region of the rat hippocampal
  72. (2010). Do astrocytes really exocytose neurotransmitters?
  73. (1992). Ecto-5'-nucleotidase is associated with cholinergic nerve terminals in the hippocampus but not in the cerebral cortex of the rat.
  74. (2006). Ectonucleotidases in the nervous system. Novartis Found. Symp.,
  75. (1997). Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones.
  76. (1993). Effect of K+ depolarization, tetrodotoxin, and NMDA receptor inhibition on extracellular adenosine levels in rat striatum.
  77. (1991). Effect of presynaptic P2 receptor stimulation on transmitter release.
  78. (1990). Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia.
  79. (1997). Effects of adenosine receptor subtypes on hippocampal extracellular serotonin level and serotonin reuptake activity.
  80. (1984). Endogenous adenosine as a modulator of hippocampal acetylcholine release. Naunyn Schmiedebergs Arch. Pharmacol.,
  81. (1991). Endogenous adenosine release from hippocampal slices: excitatory amino acid agonists stimulate release, antagonists reduce the electrically-evoked release. Naunyn Schmiedebergs Arch. Pharmacol.,
  82. (1996). Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Naunyn Schmiedebergs Arch. Pharmacol.,
  83. (1988). Evidence for pre- and postsynaptic localization of adenosine A1 receptors in the CA1 region of rat hippocampus: a quantitative autoradiographic study. Brain Res.,
  84. (1992). Evidence that ATP released from the postsynaptic site by noradrenaline, is involved in mechanical responses of guinea-pig vas deferens: cascade transmission. Neuroscience,
  85. (1994). Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked [3H]acetylcholine release from different areas of the rat hippocampus.
  86. (1999). Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices.
  87. (1987). Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia.
  88. (2001). Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.
  89. (2007). Extracellular Interconversion of nucleotides reveals an ecto-adenylate kinase activity in the rat hippocampus.
  90. (1991). Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand,
  91. (2008). FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity.
  92. (2002). G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses.
  93. (2006). GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression.
  94. (2010). Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors.
  95. (2003). High-resolution real-time recording with microelectrode biosensors reveals novel aspects of adenosine release during hypoxia in rat hippocampal slices.
  96. (2003). Homo- and heteroexchange of adenine nucleotides and nucleosides in rat hippocampal slices by the nucleoside transport system.
  97. (2000). In vivo effects of adenosine A1 receptor agonist and antagonist on neuronal and astrocytic Intermediary metabolism studied with ex vivo 13C NMR spectroscopy.
  98. (2008). In: ATP Mediated Signaling in the Nervous System. Handbook of Neurochemistry and Molecular Biology, Neurotransmitter systems,
  99. (1999). Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats.
  100. (2010). Increased binding of inhibitory neuronal receptors in the hippocampus in kainate-treated rats with spontaneous limbic seizures.
  101. (1986). Increases in cerebral Interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and
  102. (1985). Inhibition of [3H] glutamate release from rat hippocampal slices by L-phenylisopropyladenosine. Acta Physiol. Scand,
  103. (1978). Inhibition of acetylcholine release in guinea pig ileum by adenosine. Acta Physiol. Scand,
  104. (1997). Inhibition of N-,P/Q- and other types of Ca2+ channels in rat hippocampal nerve terminals by the adenosine A1 receptor.
  105. (1995). Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cyclic
  106. (1998). Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in
  107. (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
  108. (1993). Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation or energy depletion.
  109. (1993). Investigations in to the adenosine outflow from hippocampal slices evoked by ischemia-like conditions.
  110. (1995). Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices.
  111. (1999). Involvement of P2 purinoceptors and the nitric oxide pathway in [ 3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. Brain Res.,
  112. (1984). Levels of adenosine and adenine nucleotides in slices of rat hippocampus. Brain Res.,
  113. (1987). Light and electron microscopical immunocytochemistry of 5'-nucleotidase in rat cerebellum. Histochemistry,
  114. (2010). Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury.
  115. (2008). Modification of adenosine modulation of acetylcholine release in the hippocampus of aged rats.
  116. (2007). Modulation of glial cell functions by adenosine receptors.
  117. (1985). Modulation of hippocampal serotonin (5-HT) release by endogenous adenosine.
  118. (2009). Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design.
  119. (1988). Monospecific antiserum against 5'-nucleotidase from Torpedo electric organ: immunocytochemical distribution of the enzyme and its association with Schwann cell membranes. Neuroscience,
  120. (2009). Neuromodulation at single presynaptic boutons of cerebellar parallel fibers is determined by bouton size and basal action potential-evoked Ca transient amplitude.
  121. (1996). Neuronal synthesis, storage and release of ATP.
  122. (2002). Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
  123. (2005). Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal.,
  124. (2010). Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology,
  125. (2010). Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.
  126. (1999). Nucleoside transporters of mammalian cells.
  127. (2001). Parallel modification of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats.
  128. (2011). Potent effect of Interleukin-1 beta to evoke ATP and adenosine release from rat hippocampal slices.
  129. (2008). Potential therapeutic Int. erest of adenosine A2A receptors in psychiatric disorders.
  130. (1996). Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides.
  131. (1996). Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices.
  132. (1988). Presynaptic actions of carbachol and adenosine on corticostriatal synaptic transmission studied in
  133. (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers.
  134. (1993). Production of adenosine from extracellular ATP at the striatal cholinergic synapse.
  135. (1990). Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res.,
  136. (2007). Purine and pyrimidine receptors. Cell Mol. Life Sci.,
  137. (1982). Purine levels in the Intact rat brain. Studies with an implanted perfused hollow fibre.
  138. (2005). Purinergic mechanism in the immune system: A signal of danger for dendritic cells. Purinergic Signal.,
  139. (2000). Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology,
  140. (2007). Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. Neuroscience,
  141. (1997). Purinergic modulation of Interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin.
  142. (1972). Purinergic nerves.
  143. receptor inhibition improves recovery after spinal cord injury.
  144. (1990). Regional differences in the electrically stimulated release of endogenous and radioactive adenosine and purine derivatives from rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol.,
  145. (2000). Regulation of purine release.
  146. (1992). Regulatory Interactions among axon terminals affecting the release of different transmitters from rat striatal slices under hypoxic and hypoglycemic conditions.
  147. (2009). Release of adenosine and ATP during ischemia and epilepsy.
  148. (1997). Release of adenosine and ATP in the brain of the freshwater turtle (Trachemys scripta) during long-term anoxia. Brain Res.,
  149. (1985). Release of purines, noradrenaline, and GABA from rat hippocampal slices by field stimulation.
  150. (2007). Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
  151. (2003). Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology,
  152. (1999). Separation of carrier mediated and vesicular release of GABA from rat brain slices.
  153. (1989). Stimulationdependent release of adenosine triphosphate from hippocampal slices. Brain Res.,
  154. (2003). Storage and release of ATP from astrocytes in culture.
  155. (1999). Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. Stroke,
  156. (1991). Studies on the Interaction between presynaptic alpha 2-adrenoceptors and adenosine A1 receptors located on noradrenergic nerve terminals. Naunyn Schmiedebergs Arch. Pharmacol.,
  157. (2007). Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus.
  158. (2004). The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
  159. (2000). The basal ganglia.
  160. (1970). The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices.
  161. (2000). The effect of nucleotides and adenosine on stimulus-evoked glutamate release from rat brain cortical slices.
  162. (1990). The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8-substituted xanthines.
  163. (1976). The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine. Neuroscience,
  164. (1929). The physiological activity of adenine compounds with especial reference to their action upon the mammalian
  165. (1990). The release and uptake of excitatory amino acids. Trends Pharmacol. Sci.,
  166. (2001). The role and regulation of adenosine in the central nervous system.
  167. (2001). The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
  168. (1995). The source of brain adenosine outflow during ischemia and electrical stimulation.
  169. (1996). Tissue distribution of adenosine receptor mRNAs in the rat.
  170. (2009). Tuning and fine-tuning of synapses with adenosine.
  171. (2001). Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum.
  172. (1999). Uridine activates fast transmembrane Ca2+ ion fluxes in rat brain homogenates. Neuroreport,
  173. (1999). Uridine is released by depolarization and inhibits unit activity in the rat hippocampus. Neuroreport,
  174. (1998). Widespread expression of ecto-apyrase (CD39) in the central nervous system. Brain Res.,